StockMacro
Menu

Abbott Laboratories

$103.00 +19% in 6 monthsMarket cap $178.4B

ABT on XNYS, Health Care, job postings

Measures activity, not value. Not investment advice.

Net income fell 66% to $4.7B over 12 months, though quarterly revenue rose 14%.

  • GoodNew institutional positions 201, 1.6 times a year earlier
  • WatchShares up 18% in six months but down 17% over 12 months

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Industry
Pharmaceutical preparations (Health Care)
Employees
115,000
Website
abbott.com
Listed
NYSE, US
Last results
21 Oct 2026
Next results
expected around 21 Jan 2027 (an estimate: a year ago it reported on 22 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $13.0B, net income $920.0M.
Quarter to 31 Dec 2021: revenue $11.5B, net income $2.0BQuarter to 31 Dec 2021: revenue $11.5B, net income $2.0BQuarter to 31 Mar 2022: revenue $11.9B, net income $2.4BQuarter to 31 Mar 2022: revenue $11.9B, net income $2.4BQuarter to 30 Jun 2022: revenue $11.3B, net income $2.0BQuarter to 30 Jun 2022: revenue $11.3B, net income $2.0BQuarter to 30 Sep 2022: revenue $10.4B, net income $1.4BQuarter to 30 Sep 2022: revenue $10.4B, net income $1.4BQuarter to 31 Dec 2022: revenue $10.1B, net income $1.0BQuarter to 31 Dec 2022: revenue $10.1B, net income $1.0BQuarter to 31 Mar 2023: revenue $9.7B, net income $1.3BQuarter to 31 Mar 2023: revenue $9.7B, net income $1.3BQuarter to 30 Jun 2023: revenue $10.0B, net income $1.4BQuarter to 30 Jun 2023: revenue $10.0B, net income $1.4BQuarter to 30 Sep 2023: revenue $10.1B, net income $1.4BQuarter to 30 Sep 2023: revenue $10.1B, net income $1.4BQuarter to 31 Dec 2023: revenue $10.2B, net income $1.6BQuarter to 31 Dec 2023: revenue $10.2B, net income $1.6BQuarter to 31 Mar 2024: revenue $10.0B, net income $1.2BQuarter to 31 Mar 2024: revenue $10.0B, net income $1.2BQuarter to 30 Jun 2024: revenue $10.4B, net income $1.3BQuarter to 30 Jun 2024: revenue $10.4B, net income $1.3BQuarter to 30 Sep 2024: revenue $10.6B, net income $1.6BQuarter to 30 Sep 2024: revenue $10.6B, net income $1.6BQuarter to 31 Dec 2024: revenue $11.0B, net income $9.2BQuarter to 31 Dec 2024: revenue $11.0B, net income $9.2BQuarter to 31 Mar 2025: revenue $10.4B, net income $1.3BQuarter to 31 Mar 2025: revenue $10.4B, net income $1.3BQuarter to 30 Jun 2025: revenue $11.1B, net income $1.8BQuarter to 30 Jun 2025: revenue $11.1B, net income $1.8BQuarter to 30 Sep 2025: revenue $11.4B, net income $1.6BQuarter to 30 Sep 2025: revenue $11.4B, net income $1.6BQuarter to 31 Dec 2025: revenue $11.5B, net income $1.8BQuarter to 31 Dec 2025: revenue $11.5B, net income $1.8BQuarter to 31 Mar 2026: revenue $11.2B, net income $1.1BQuarter to 31 Mar 2026: revenue $11.2B, net income $1.1BQuarter to 30 Jun 2026: revenue $12.6B, net income $928.0MQuarter to 30 Jun 2026: revenue $12.6B, net income $928.0MQuarter to 30 Sep 2026: revenue $13.0B, net income $920.0MQuarter to 30 Sep 2026: revenue $13.0B, net income $920.0M
31 Dec 2021RevenueNet incometallest bar $13.0B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$13.0B$920.0M
30 Jun 2026$12.6B$928.0M
31 Mar 2026$11.2B$1.1B
31 Dec 2025$11.5B$1.8B
30 Sep 2025$11.4B$1.6B
30 Jun 2025$11.1B$1.8B
31 Mar 2025$10.4B$1.3B
31 Dec 2024$11.0B$9.2B
30 Sep 2024$10.6B$1.6B
30 Jun 2024$10.4B$1.3B
31 Mar 2024$10.0B$1.2B
31 Dec 2023$10.2B$1.6B
30 Sep 2023$10.1B$1.4B
30 Jun 2023$10.0B$1.4B
31 Mar 2023$9.7B$1.3B
31 Dec 2022$10.1B$1.0B
30 Sep 2022$10.4B$1.4B
30 Jun 2022$11.3B$2.0B
31 Mar 2022$11.9B$2.4B
31 Dec 2021$11.5B$2.0B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $48.2B $43.8B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +10% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $4.7B $14.0B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.69 $7.97
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 56.9% 55.9% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 13.8% 17.6% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 9.7% 31.9% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 9.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $6.8B $6.9B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $4.3B $7.7B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $31.2B $12.9B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $26.9B $5.2B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.61 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $29.46
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 37.9 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.7 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 4.3 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.5 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 2.3% 2.5%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Abbott LaboratoriesABT (this company) $178.4B37.93.7+10%9.7%
PfizerPFE $156.2B38.72.5+1.3%6.3%
Vertex PharmaceuticalsVRTX $130.6B32.810.1+10%30.7%
Bristol-Myers SquibbBMY $120.2B13.02.4+4.2%18.5%
MerckMRK $329.7B1344.9+4.9%3.6%
Regeneron PharmaceuticalsREGN $95.2B19.85.6+19%28.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$46.6M

bought $0, sold $46.6M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.0%

2,994 13F filers vs 2,907

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

78%

1.4B shares held by 13F filers (30 Sep 2026) of 1.7B outstanding (30 Sep 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.1%

19.1M shares sold short (30 Oct 2026) of 1.7B outstanding (30 Sep 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.9

19.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+9.6%

17.4M shares sold short in the report before, 19.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

28%

28% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+51%

125 vs 83 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+14%

$13.0B vs $11.4B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+3.4%

$513.0M vs $496.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$147.8M

the 12 months before: $133.1M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$5.4M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

41

41 articles in the last 7 days; its usual week has 7.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.5×

41 articles in the last 7 days; its usual week has 7.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 201, 1.6× a year earlier

Price $103.00 on 20 Nov 2026, -17% over 12 months (12-month range $82.56 to $128.90)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $43.3M in the last 12 months (the 12 months before: -$79.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 125 published in the last 12 months, +51% on the 12 months before.
Revenue per quarter. Revenue $13.0B in the latest quarter, +14% on a year earlier.
Capital spending per quarter. Capital spending $513.0M in the latest quarter, +3.4% on a year earlier.
Institutional holders (13F filers). 2,994 13F filers reported holding it in the latest 13F quarter, -0.6% on a year earlier.
Federal obligations. Federal obligations: $201.8M published in the last 12 months, +42% on the 12 months before.
Lobbying spend. Lobbying spend: $5.4M published in the last 12 months, -2.4% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 201 vs usual 129 (2026-09-30); 1.6x the same period a year earlier
13 Nov 20268-K and other filingsChange-in-control agreements extended through Dec 31, 2028 for named executive officers other than Chairman and CEO Robert B. Ford, whose agreement expires Dec 31, 2026
13 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2026Lobbying filingnew lobbying registration (THE DUBERSTEIN GROUP INC.)
14 Oct 2026Lobbying filingnew lobbying registration (DUDDINGTON GLOBAL STRATEGIES LLC)
27 Apr 20268-K and other filingsDirector or officer change
27 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Apr 2026Lobbying filingnew lobbying registration (PHRONESISDC, LLC)
15 Feb 2026Sharp changeFirst award from a new federal agency: first award from a new federal agency (Department of the Interior): PEMBROOKE OCCUPATIONAL HEALTH, INC.: new Department of the Interior contract 140D0426F0156 ($1,158,342)
20 Jan 2026Lobbying filinglobbying engagement terminated (BALLARD PARTNERS)
12 Dec 20258-K and other filingsDirector or officer change
12 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Nov 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 8,276 vs usual 4,417 (2025-11-17..2025-11-23); 1.4x the same week a year earlier
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 213 vs usual 108 (2025-03-31); 1.7x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 21.1M vs usual 14.0M (2025-04-30); 1.5x the same period a year earlier
1 May 20258-K and other filingsDirector or officer change
1 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Apr 2025Sharp changeShort interest spike: short interest spike, 21.7M vs usual 13.8M (2025-04-15); 1.7x the same period a year earlier
15 Apr 2025Sharp changeShort interest spike: short interest spike, 21.8M vs usual 13.8M (2025-03-31); 1.5x the same period a year earlier
10 Apr 2025Lobbying filinglobbying engagement terminated (BGR GOVERNMENT AFFAIRS)
1 Apr 2025Sharp changeShort interest spike: short interest spike, 21.9M vs usual 13.8M (2025-03-14); 1.4x the same period a year earlier
24 Mar 2025Lobbying filingnew lobbying registration (MARSHALL & POPP, LLC)
18 Mar 2025Sharp changeShort interest spike: short interest spike, 22.9M vs usual 13.8M (2025-02-28); 1.5x the same period a year earlier
10 Mar 2025Lobbying filingnew lobbying registration (S-3 GROUP)
4 Mar 2025Sharp changeShort interest spike: short interest spike, 22.3M vs usual 13.8M (2025-02-14); 1.6x the same period a year earlier
16 Feb 2025Lobbying filingnew lobbying registration (TIBER CREEK GROUP)
21 Jan 2025Lobbying filinglobbying engagement terminated (THEGROUP DC, LLC)
10 Jan 2025Lobbying filinglobbying engagement terminated (IMPACT HEALTH POLICY PARTNERS)
15 Nov 20248-K and other filingsDirector or officer change
15 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 May 20248-K and other filingsDirector or officer change
1 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Jan 20248-K and other filingsA major agreement ended
12 Jun 20238-K and other filingsDirector or officer change
12 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Apr 2023Lobbying filinglobbying engagement terminated (JEFF MILLER GROUP)
10 Feb 2023Lobbying filingnew lobbying registration (BALLARD PARTNERS)
21 Oct 20228-K and other filingsDirector or officer change
15 Sep 20228-K and other filingsDirector or officer change
15 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 May 2022Sharp changeWikipedia attention spike: wikipedia attention spike, 16K vs usual 6,258 (2022-05-09..2022-05-15); 2.4x the same week a year earlier
13 Dec 20218-K and other filingsDirector or officer change
10 Dec 20218-K and other filingsDirector or officer change
10 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$46.8M published
Month from 1 Feb 2022: -$291K published
Month from 1 Mar 2022: -$1.8M published
Month from 1 May 2022: -$8.4M published
Month from 1 Jul 2022: -$5.8M published
Month from 1 Aug 2022: -$13.6M published
Month from 1 Sep 2022: -$2.5M published
Month from 1 Nov 2022: -$4.9M published
Month from 1 Dec 2022: -$1.2M published
Month from 1 Jan 2023: -$457K published
Month from 1 Feb 2023: -$27K published
Month from 1 Mar 2023: -$1.5M published
Month from 1 May 2023: -$6.5M published
Month from 1 Jun 2023: -$848K published
Month from 1 Jul 2023: -$5.7M published
Month from 1 Aug 2023: -$1.1M published
Month from 1 Oct 2023: -$4.7M published
Month from 1 Dec 2023: -$1.6M published
Month from 1 Feb 2024: -$6.3M published
Month from 1 Mar 2024: -$528K published
Month from 1 May 2024: -$3.5M published
Month from 1 Sep 2024: -$16.5M published
Month from 1 Oct 2024: -$18.4M published
Month from 1 Jan 2025: -$337K published
Month from 1 Feb 2025: -$64.8M published
Month from 1 Mar 2025: -$12.8M published
Month from 1 May 2025: -$337K published
Month from 1 Aug 2025: -$747K published
Month from 1 Nov 2025: -$203K published
Month from 1 Jan 2026: $2.0M published
Month from 1 Feb 2026: $1.1M published
Month from 1 Mar 2026: -$485K published
Month from 1 Apr 2026: $1.1M published
Month from 1 Jun 2026: $174K published
Month from 1 Aug 2026: -$46.8M published
Month from 1 Sep 2026: -$3K published
Month from 1 Nov 2026: -$406K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 27 published
Quarter from 1 Apr 2022: 27 published
Quarter from 1 Jul 2022: 37 published
Quarter from 1 Oct 2022: 16 published
Quarter from 1 Jan 2023: 14 published
Quarter from 1 Apr 2023: 21 published
Quarter from 1 Jul 2023: 21 published
Quarter from 1 Oct 2023: 13 published
Quarter from 1 Jan 2024: 19 published
Quarter from 1 Apr 2024: 18 published
Quarter from 1 Jul 2024: 28 published
Quarter from 1 Oct 2024: 22 published
Quarter from 1 Jan 2025: 19 published
Quarter from 1 Apr 2025: 13 published
Quarter from 1 Jul 2025: 33 published
Quarter from 1 Oct 2025: 18 published
Quarter from 1 Jan 2026: 24 published
Quarter from 1 Apr 2026: 23 published
Quarter from 1 Jul 2026: 24 published
Quarter from 1 Oct 2026: 54 published
Revenue per quarter
Quarter ended 31 Dec 2021: $11.5B, +7.2% on a year earlier; public on 19 Feb 2022
Quarter ended 31 Mar 2022: $11.9B, +14% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $11.3B, +10% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $10.4B, -4.7% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $10.1B, -12% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $9.7B, -18% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $10.0B, -11% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $10.1B, -2.6% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $10.2B, +1.5% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $10.0B, +2.2% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $10.4B, +4.0% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $10.6B, +4.9% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $11.0B, +7.2% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $10.4B, +4.0% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $11.1B, +7.4% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $11.4B, +6.9% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $11.5B, +4.4% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $11.2B, +7.8% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $12.6B, +13% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $13.0B, +14% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $614.0M, -9.6% on a year earlier; public on 19 Feb 2022
Quarter ended 31 Mar 2022: $321.0M, -19% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $379.0M, -8.2% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $467.0M, +1.3% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $610.0M, -0.7% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $380.0M, +18% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $507.0M, +34% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $560.0M, +20% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $755.0M, +24% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $398.0M, +4.7% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $533.0M, +5.1% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $556.0M, -0.7% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $720.0M, -4.6% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $484.0M, +22% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $502.0M, -5.8% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $496.0M, -11% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $689.0M, -4.3% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $399.0M, -18% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $497.0M, -1.0% on a year earlier; public on 29 Jul 2026
Quarter ended 30 Sep 2026: $513.0M, +3.4% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 2,478; public on 14 Feb 2022
31 Mar 2022 report: 2,565; public on 16 May 2022
30 Jun 2022 report: 2,522; public on 15 Aug 2022
30 Sep 2022 report: 2,394; public on 14 Nov 2022
31 Dec 2022 report: 2,504; public on 14 Feb 2023
31 Mar 2023 report: 2,505; public on 15 May 2023
30 Jun 2023 report: 2,504; public on 14 Aug 2023
30 Sep 2023 report: 2,475; public on 14 Nov 2023
31 Dec 2023 report: 2,656; public on 14 Feb 2024
31 Mar 2024 report: 2,733; public on 15 May 2024
30 Jun 2024 report: 2,699; public on 14 Aug 2024
30 Sep 2024 report: 2,744; public on 14 Nov 2024
31 Dec 2024 report: 2,864; public on 14 Feb 2025
31 Mar 2025 report: 3,019; public on 15 May 2025
30 Jun 2025 report: 3,035; public on 14 Aug 2025
30 Sep 2025 report: 3,013; public on 14 Nov 2025
31 Dec 2025 report: 3,122; public on 17 Feb 2026
31 Mar 2026 report: 3,004; public on 15 May 2026
30 Jun 2026 report: 2,907; public on 14 Aug 2026
30 Sep 2026 report: 2,994; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $12.8M published
Month from 1 Dec 2021: $656.0M published
Month from 1 Jan 2022: $404.8M published
Month from 1 Feb 2022: $142.0M published
Month from 1 Mar 2022: $13.1M published
Month from 1 Apr 2022: $322.5M published
Month from 1 May 2022: $15.9M published
Month from 1 Jun 2022: $1.0B published
Month from 1 Jul 2022: $36.7M published
Month from 1 Aug 2022: $13.4M published
Month from 1 Sep 2022: $1.5M published
Month from 1 Oct 2022: $6.5M published
Month from 1 Nov 2022: -$16.7M published
Month from 1 Dec 2022: $90.4M published
Month from 1 Jan 2023: $45.3M published
Month from 1 Feb 2023: $9.7M published
Month from 1 Mar 2023: $260.7M published
Month from 1 Apr 2023: $6.2M published
Month from 1 May 2023: $6.4M published
Month from 1 Jun 2023: $8.3M published
Month from 1 Jul 2023: $12.4M published
Month from 1 Aug 2023: $2.4M published
Month from 1 Sep 2023: $10.9M published
Month from 1 Oct 2023: $50.8M published
Month from 1 Nov 2023: $8.3M published
Month from 1 Dec 2023: $11.1M published
Month from 1 Jan 2024: $5.6M published
Month from 1 Feb 2024: $4.9M published
Month from 1 Mar 2024: $1.2M published
Month from 1 Apr 2024: $6.5M published
Month from 1 May 2024: -$367K published
Month from 1 Jun 2024: $2.6M published
Month from 1 Jul 2024: $6.6M published
Month from 1 Aug 2024: $8.2M published
Month from 1 Sep 2024: $6.3M published
Month from 1 Oct 2024: $15.2M published
Month from 1 Nov 2024: $3.0M published
Month from 1 Dec 2024: $10.0M published
Month from 1 Jan 2025: $44.6M published
Month from 1 Feb 2025: $9.9M published
Month from 1 Mar 2025: $3.5M published
Month from 1 Apr 2025: $7.1M published
Month from 1 May 2025: -$2.3M published
Month from 1 Jun 2025: $5.7M published
Month from 1 Jul 2025: $6.7M published
Month from 1 Aug 2025: $5.9M published
Month from 1 Sep 2025: $6.7M published
Month from 1 Oct 2025: $31.0M published
Month from 1 Nov 2025: $13.4M published
Month from 1 Dec 2025: $9.5M published
Month from 1 Jan 2026: $42.7M published
Month from 1 Feb 2026: $7.3M published
Month from 1 Mar 2026: $7.5M published
Month from 1 Apr 2026: $1.2M published
Month from 1 May 2026: $6.5M published
Month from 1 Jun 2026: $30.1M published
Month from 1 Jul 2026: $5.2M published
Month from 1 Aug 2026: $15.9M published
Month from 1 Sep 2026: $15.5M published
Month from 1 Oct 2026: $58.3M published
Month from 1 Nov 2026: $2.1M published
Lobbying spend
Quarter from 1 Jan 2022: $1.3M published
Quarter from 1 Apr 2022: $1.2M published
Quarter from 1 Jul 2022: $2.5M published
Quarter from 1 Jan 2023: $1.5M published
Quarter from 1 Apr 2023: $1.4M published
Quarter from 1 Jul 2023: $1.1M published
Quarter from 1 Oct 2023: $1.4M published
Quarter from 1 Jan 2024: $1.0M published
Quarter from 1 Apr 2024: $1.6M published
Quarter from 1 Jul 2024: $1.1M published
Quarter from 1 Oct 2024: $1.3M published
Quarter from 1 Jan 2025: $1.3M published
Quarter from 1 Apr 2025: $2.0M published
Quarter from 1 Jul 2025: $954K published
Quarter from 1 Oct 2025: $1.3M published
Quarter from 1 Jan 2026: $1.0M published
Quarter from 1 Apr 2026: $1.6M published
Quarter from 1 Jul 2026: $1.3M published
Quarter from 1 Oct 2026: $1.5M published

What is unusual now

  • Made public in the last 90 days: it saw 201 13F filers open a new position in the quarter ended 30 Sep 2026, 1.6× the same quarter last year.
  • Many funds opening a new position: saw 201 13F filers open a new position in the quarter ended 30 Sep 2026, 1.6× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $43.3M in the last 12 months (the 12 months before: -$79.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 125 published in the last 12 months, +51% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 3 sales, $46.6M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
6 Nov 2026Mary K MorelandEXECUTIVE VICE PRESIDENTSell3,500$116.00$406KForm 4
3 Sep 2026John A. McCoy Jr.VICE PRESIDENT AND CONTROLLERSell27$109.54$3KForm 4
27 Aug 2026Robert B FordCHAIRMAN AND CEOSellafter exercising options398,832$115.85$46.2MForm 4
13 Aug 2026Louis H. MorroneEXECUTIVE VICE PRESIDENTSell5,850$109.83$643KForm 4
18 Jun 2026John G StrattonDirectorBuy2,000$86.82$174KForm 4
28 Apr 2026Daniel J StarksDirectorBuy10,000$92.65$926KForm 4
27 Apr 2026Philip P BoudreauEVP AND CFOBuy2,200$91.50$201KForm 4
3 Mar 2026Louis H. MorroneEXECUTIVE VICE PRESIDENTSell1,144$115.58$132KForm 4

2,994 institutions reported shares at the end of Q3 2026, 78% of the shares outstanding; 199 opened a position, 123 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.151.7M8.76%$15.0B-897K-0.6%
Vanguard Capital Management LLC113.3M6.54%$11.2B-499K-0.4%
State Street Corp81.4M4.70%$8.0B+505K+0.6%
Charles Schwab Investment Management Inc57.2M3.30%$5.6B-2.5M-4.2%
Vanguard Portfolio Management LLC47.9M2.77%$4.7B-1.1M-2.2%
Capital Research Global Investors45.0M2.60%$4.4B+8.1M+22%
Geode Capital Management, LLC39.6M2.29%$3.9B+369K+0.9%
Capital International Investors35.5M2.05%$3.5B+805K+2.3%
JPMorgan Chase & Co29.7M1.72%$3.0B+14.6M+97%
Morgan Stanley28.9M1.67%$2.9B+2.3M+8.8%

Institutions that added the most shares between Q2 2026 and Q3 2026.

InstitutionShares% of companyValueChange vs Q2 2026
JPMorgan Chase & Co29.7M1.72%$3.0B+14.6M+97%
Capital Research Global Investors45.0M2.60%$4.4B+8.1M+22%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main4.8M0.28%$473.3M+4.4M12 times as many
T. Rowe Price Investment Management, Inc.4.1M0.24%+3.8M15 times as many
AQR Capital Management LLC7.2M0.42%$715.6M+3.0M+73%

Federal contracts

All 366 federal contracts

28 new awards in 12 months, $48.2M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
2 Oct 2026Department of Veterans Affairs$1.9Mup to $9.2MLAB COST PER TESTUSAspending
2 Oct 2026Department of Veterans Affairs$1.4Mup to $8.3MCPRR CHEMISTRYUSAspending
1 Oct 2026Department of Veterans Affairs$1.3MCHEMISTRY & IMMUNOASSAY ANALYZER CPRRUSAspending
1 Oct 2026Department of Veterans Affairs$2.1MEXERCISE ORDERING PERIODUSAspending
1 Oct 2026Department of Veterans Affairs$2.9MEXERCISE ORDERING PERIODUSAspending
1 Oct 2026Department of Veterans Affairs$1.1MVAPAHCS CHEMISTRY & IMMUNOASSAY ANALYZER CPRRUSAspending
1 Oct 2026Department of Veterans Affairs$1.4MEL PASO VETERANS HEALTH CARE SYSTEM IMMUNOASSAY COST-PER-REPORTABLE RESULT (CPRR)USAspending
1 Oct 2026Department of Veterans Affairs$1.4MJAMES H. QUILLEN OY1 ORDER AGAINST THE ABBOTT IMMUNOCHEMISTRY LAB BPA.USAspending

Company events

All 57 company events

In 12 months: 3 director or officer changes, 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
13 Nov 2026Change-in-control agreements extended through Dec 31, 2028 for named executive officers other than Chairman and CEO Robert B. Ford, whose agreement expires Dec 31, 20268-K
27 Apr 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
9 Mar 2026Signed a major agreementSame filing: took on new debt8-K
26 Feb 2026Signed a major agreement8-K
12 Dec 2025Director or officer changeSame filing: changed its bylaws or fiscal year8-K
20 Nov 2025Signed a major agreement8-K
1 May 2025Director or officer change8-K
15 Nov 2024Director or officer change8-K

Reported lobbying spend: $1.5M in Q3 2026, $1.3M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
15 Sep 2026NewThe Duberstein Group Inc.for Abbott LaboratoriesIssues related to health care, Medicare, medical devices, cancer screeningHealth issues, Medicare/Medicaid, TaxationFiling
1 Sep 2026NewDuddington Global Strategies LLCfor Abbott LaboratoriesLobbying issues related to veterans healthcare.VETFiling
1 Apr 2026NewPhronesisdc, LLCfor Abbott LaboratoriesIssues related to commercial litigation; Issues related to pension matters.RET, Taxation, Health issues, TORFiling
31 Dec 2025EndedBallard Partnersfor Mcdermott+ Consulting (On Behalf Of Abbott Diabetes Care)Educate House and Senate members on Diabetes Care issues. Expand the use and prescribing of Continuous Glucose Monitors.VETFiling
1 Mar 2025EndedBGR Government Affairsfor Abbott LaboratoriesGlobal health issuesHealth issuesFiling
7 Feb 2025NewMarshall & Popp, LLCfor Abbott LaboratoriesIssues related to infant formula.Health issues, Trade, Taxation, Agriculture, BudgetFiling
1 Jan 2025NewS-3 Groupfor Abbott LaboratoriesEquitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formulaHealth issues, Medicare/Medicaid, Agriculture, TaxationFiling
1 Jan 2025NewTiber Creek Groupfor Abbott LaboratoriesGlobal health policy and funding.Health issues, FOR, BudgetFiling

Layoff notices

All 8 layoff notices

No notice in 12 months; the latest is dated 1 Jan 2014. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Jan 2014Abbott Point of CarePrinceton, NJ8031 Mar 2014Notice
1 Oct 2011Abbott Point of CarePrinceton, NJ5130 Sep 2011Notice
1 Mar 2010ST. JUDE MEDICALWEST BERLIN, NJ3130 Jun 2010Notice
1 Dec 2008ABBOTT LABORATORIESEDISON, NJ1434 Feb 2009Notice
1 Aug 2008ABBOTT LABORATORIESWHIPPANY, NJ12511 Oct 2008Notice
1 Jun 2008ABBOTT LABORATORIESPARSIPPANY, NJ8329 Aug 2008Notice
1 Nov 2007Abbott LaboratoriesLake County, IL1011 Nov 2007closureNotice
13 Jul 2005Abbott LaboratoriesLake County, IL6911 Sep 2005closureNotice

The 5 newest of 490 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 May 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Abbott Laboratories (ABT): had 21.8M shares sold short in the 31 Mar 2025 report, 1.5× the same report last year, while it saw 213 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year. Two unrelated kinds of activity within 30 days.

  • Short interest and volume: Short interest spike, became public on 10 Apr 2025
  • Short interest and volume: Short interest spike, became public on 26 Apr 2025
  • Short interest and volume: Short interest spike, became public on 10 May 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
2024-03-28: 14.5M2024-04-15: 12.9M2024-04-30: 14.5M2024-05-15: 14.8M2024-05-31: 14.5M2024-06-14: 11.6M2024-06-28: 13.0M2024-07-15: 10.7M2024-07-31: 13.6M2024-08-15: 12.7M2024-08-30: 12.8M2024-09-13: 13.4M2024-09-30: 11.8M2024-10-15: 14.0M2024-10-31: 14.1M2024-11-15: 12.1M2024-11-29: 13.6M2024-12-13: 12.1M2024-12-31: 14.3M2025-01-15: 15.0M2025-01-31: 18.2M2025-02-14: 22.3M2025-02-28: 22.9M2025-03-14: 21.9M2025-03-31: 21.8M
The 31 Mar 2025 report against the 24 reports before it. this reportearliernormal: 13.8M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 10 Apr 2025

Abbott Laboratories had 21.8M shares sold short in the 31 Mar 2025 report, 1.5× the same report last year.

This period
21.8M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
13.8M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+5.3
Same report last year
14.5M
History used
2,649 days
2024-03-28: 14.5M2024-04-15: 12.9M2024-04-30: 14.5M2024-05-15: 14.8M2024-05-31: 14.5M2024-06-14: 11.6M2024-06-28: 13.0M2024-07-15: 10.7M2024-07-31: 13.6M2024-08-15: 12.7M2024-08-30: 12.8M2024-09-13: 13.4M2024-09-30: 11.8M2024-10-15: 14.0M2024-10-31: 14.1M2024-11-15: 12.1M2024-11-29: 13.6M2024-12-13: 12.1M2024-12-31: 14.3M2025-01-15: 15.0M2025-01-31: 18.2M2025-02-14: 22.3M2025-02-28: 22.9M2025-03-14: 21.9M2025-03-31: 21.8M
the 31 Mar 2025 report24 earlier reportsnormal: 13.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Apr 2025

Abbott Laboratories had 21.7M shares sold short in the 15 Apr 2025 report, 1.7× the same report last year.

This period
21.7M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
13.8M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.9
Same report last year
12.9M
History used
2,664 days
2024-04-15: 12.9M2024-04-30: 14.5M2024-05-15: 14.8M2024-05-31: 14.5M2024-06-14: 11.6M2024-06-28: 13.0M2024-07-15: 10.7M2024-07-31: 13.6M2024-08-15: 12.7M2024-08-30: 12.8M2024-09-13: 13.4M2024-09-30: 11.8M2024-10-15: 14.0M2024-10-31: 14.1M2024-11-15: 12.1M2024-11-29: 13.6M2024-12-13: 12.1M2024-12-31: 14.3M2025-01-15: 15.0M2025-01-31: 18.2M2025-02-14: 22.3M2025-02-28: 22.9M2025-03-14: 21.9M2025-03-31: 21.8M2025-04-15: 21.7M
the 15 Apr 2025 report24 earlier reportsnormal: 13.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2025

Abbott Laboratories had 21.1M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.

This period
21.1M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
14.0M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+3.6
Same report last year
14.5M
History used
2,679 days
2024-04-30: 14.5M2024-05-15: 14.8M2024-05-31: 14.5M2024-06-14: 11.6M2024-06-28: 13.0M2024-07-15: 10.7M2024-07-31: 13.6M2024-08-15: 12.7M2024-08-30: 12.8M2024-09-13: 13.4M2024-09-30: 11.8M2024-10-15: 14.0M2024-10-31: 14.1M2024-11-15: 12.1M2024-11-29: 13.6M2024-12-13: 12.1M2024-12-31: 14.3M2025-01-15: 15.0M2025-01-31: 18.2M2025-02-14: 22.3M2025-02-28: 22.9M2025-03-14: 21.9M2025-03-31: 21.8M2025-04-15: 21.7M2025-04-30: 21.1M
the 30 Apr 2025 report24 earlier reportsnormal: 14.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2025

Abbott Laboratories saw 213 13F filers open a new position in the quarter ended 31 Mar 2025, 1.7× the same quarter last year.

This period
213 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
108
Typical spread (median absolute deviation)
14
How far from its usual level
+5.1
Same quarter last year
124
History used
4,200 days
2023-03-31: 962023-06-30: 1132023-09-30: 1032023-12-31: 1342024-03-31: 1242024-06-30: 1002024-09-30: 1352024-12-31: 832025-03-31: 213
the quarter ended 31 Mar 20258 earlier quartersnormal: 108

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 201 13F filers open a new position in the quarter ended 30 Sep 2026, 1.6× the same quarter last year.

    Same quarter last year: 123; its normal quarter is 129.

    See the evidence
    This period
    201 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    129
    Typical spread (median absolute deviation)
    6
    How far from its usual level
    +5.6
    Same quarter last year
    123
    History used
    4,748 days
    2024-09-30: 1352024-12-31: 832025-03-31: 2132025-06-30: 1262025-09-30: 1232025-12-31: 1272026-03-31: 1312026-06-30: 1462026-09-30: 201
    the quarter ended 30 Sep 20268 earlier quartersnormal: 129

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 13 Nov 2026Filings change

    filed a director or officer change: Change-in-control agreements extended through Dec 31, 2028 for named executive officers other than Chairman and CEO Robert B. Ford, whose agreement expires Dec 31, 2026.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 13 Nov 2026Filings record

    Change-in-control agreements extended through Dec 31, 2028 for named executive officers other than Chairman and CEO Robert B. Ford, whose agreement expires Dec 31, 2026

  4. 20 Oct 2026Lobbying record

    ABBOTT LABORATORIES: new lobbying registration (THE DUBERSTEIN GROUP INC.) (dated 15 Sep 2026)

  5. 14 Oct 2026Lobbying record

    ABBOTT LABORATORIES: new lobbying registration (DUDDINGTON GLOBAL STRATEGIES LLC) (dated 1 Sep 2026)

  6. 8 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24827N0082 ($1.9M) (dated 2 Oct 2026)

  7. 8 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24527N0053 ($1.4M) (dated 2 Oct 2026)

  8. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26127N0114 ($1.3M) (dated 1 Oct 2026)

  9. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26127N0101 ($2.1M) (dated 1 Oct 2026)

  10. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26127N0094 ($2.9M) (dated 1 Oct 2026)

  11. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26127N0025 ($1.1M) (dated 1 Oct 2026)

  12. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C25727N0016 ($1.4M) (dated 1 Oct 2026)

  13. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24927N0216 ($1.4M) (dated 1 Oct 2026)

  14. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24927N0147 ($1.5M) (dated 1 Oct 2026)

  15. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24927N0144 ($1.3M) (dated 1 Oct 2026)

  16. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24927N0143 ($1.1M) (dated 1 Oct 2026)

  17. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24927N0020 ($1.6M) (dated 1 Oct 2026)

  18. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24927N0019 ($1.2M) (dated 1 Oct 2026)

  19. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24827N0001 ($1.9M) (dated 1 Oct 2026)

  20. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24127N0061 ($1.1M) (dated 1 Oct 2026)

  21. 7 Oct 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24127N0044 ($1.6M) (dated 1 Oct 2026)

  22. 23 Sep 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C25026N0813 ($3.0M) (dated 17 Sep 2026)

  23. 6 Sep 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24426N1007 ($1.5M) (dated 31 Aug 2026)

  24. 24 Aug 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C25526N0386 ($1.5M) (dated 18 Aug 2026)

  25. 12 Aug 2026Institutional holdings record

    BARROW HANLEY MEWHINNEY & STRAUSS LLC opened a $324.0M position (2026Q2 13F)

  26. 23 Jul 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26326N0588 ($2.0M) (dated 17 Jul 2026)

  27. 23 Jul 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26326N0587 ($1.1M) (dated 17 Jul 2026)

  28. 7 Jul 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26026F0304 ($2.4M) (dated 1 Jul 2026)

  29. 19 Jun 2026Insiders record

    Stratton John G (director) bought 2,000 shares of ABT ($173,640) (dated 18 Jun 2026)

  30. 15 May 2026Institutional holdings record

    TWO SIGMA INVESTMENTS, LP opened a $656.0M position (2026Q1 13F)

  31. 29 Apr 2026Insiders record

    STARKS DANIEL J (director) bought 10,000 shares of ABT ($926,500) (dated 28 Apr 2026)

  32. 28 Apr 2026Insiders record

    Boudreau Philip P (EVP AND CFO) bought 2,200 shares of ABT ($201,300) (dated 27 Apr 2026)

  33. 27 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 27 Apr 2026Filings record

    Director or officer change

  35. 27 Apr 2026Lobbying record

    ABBOTT LABORATORIES: new lobbying registration (PHRONESISDC, LLC) (dated 1 Apr 2026)

  36. 6 Apr 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24826N0460 ($3.4M) (dated 31 Mar 2026)

  37. 29 Mar 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26226N0485 ($1.2M) (dated 23 Mar 2026)

  38. 25 Mar 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C24826N0321 ($1.3M) (dated 19 Mar 2026)

  39. 14 Mar 2026Government contracts record

    ABBOTT LABORATORIES INC.: new Department of Veterans Affairs contract 36C26226N0420 ($1.3M) (dated 8 Mar 2026)

  40. 15 Feb 2026Government contracts change

    won its first award from the Department of the Interior, a $1.2M contract, after 339 earlier federal awards from other agencies.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    339

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Showing the newest 40 of 149 entries; narrow the window or the kind of data to see older ones.

Not listed: 444 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000001800
Ticker
ABT
Domain
abbott.com
Employer name
ameditech, evalve, Abbott Cardiovascular Systems Inc., Abbott Diabetes Care Inc. and 14 more (16 unverified)
Fein
20-2507302, 22-3890190, 26-1444559, 27-2047994 and 8 more (12 unverified)
Hq location
IL|ABBOTT PARK|60064 (1 unverified)
Lobbying client
abbott, abbott fka csi office based facility assn obfa fka uspa, abbott formerly known as alere, abbott laboratories and 4 more
Name
3-102-920937, Sociedad de Responsabilidad Limitada, 3A Nutrition (Vietnam) Company Limited, Abbott, Abbott Affiliate Holdings Limited and 491 more
Uei
CHBQGDL3FLQ8, EF9EAJ1MF6U3, HQ4DE67K3S86, L3AXXYLB3V56 and 4 more
Wikidata
Q306764
Wikipedia
Abbott Laboratories
  • DOL H-1B labor condition applications and PERM certifications1442 data points7 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)135 records, 279 data points1 May 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings8 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)172 records28 Jan 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1290 data points31 Dec 2006 to 30 Sep 2026
  • SEC Form 4 insider transactions338 records, 664 data points17 Feb 2016 to 6 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards366 records, 17109 data points1 Oct 2007 to 19 Nov 2026
  • WARN layoff notices (state labor agencies)8 records, 24 data points11 Jul 2005 to 1 Jan 2014
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026